Pyxis Oncology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Pyxis Oncology, Inc. (PYXS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 347.83 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-13
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 266.65K shares, a 142.50% increase year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 81.19K shares, a 86.18% decline year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 81.82K shares, a 2470.56% increase year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 657.49K shares.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 1.44M shares, a 1318.92% increase from fiscal 2024.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 101.24K shares, a 86.02% decline from fiscal 2023.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 724.02K shares, a 13.20% decline from fiscal 2022.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 834.10K shares, a 45.10% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 266.65K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 347.83K shares 10-Q · filed 2026-08-13 | 429.66K shares derived: sum of 3 quarters · filed 2026-08-13 | 1.09M shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 81.19K shares 10-Q · filed 2026-05-14 | 163.01K shares derived: sum of 2 quarters · filed 2026-05-14 | 820.50K shares derived: sum of 3 quarters · filed 2026-05-14 | 930.45K shares derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | 81.82K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | 739.31K shares derived: sum of 2 quarters · filed 2026-03-23 | 849.27K shares derived: sum of 3 quarters · filed 2026-03-23 | 1.44M shares 10-K · filed 2026-03-23 |
| 2025-09-30 | 657.49K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | 767.45K shares derived: sum of 2 quarters · filed 2025-11-03 | 1.35M shares 10-Q · filed 2025-11-03 | 1.36M shares derived: sum of 4 quarters · filed 2025-11-03 |
| 2025-06-30 | 109.96K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 697.24K shares 10-Q · filed 2025-08-14 | 700.42K shares derived: sum of 3 quarters · filed 2025-08-14 | 668.25K shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 587.28K shares 10-Q · filed 2025-05-15 | 590.46K shares derived: sum of 2 quarters · filed 2025-05-15 | 558.29K shares derived: sum of 3 quarters · filed 2025-05-15 | 636.24K shares derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-12-31 | 3.18K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -28.99K shares derived: sum of 2 quarters · filed 2025-03-18 | 48.96K shares derived: sum of 3 quarters · filed 2025-03-18 | 101.24K shares 10-K · filed 2025-03-18 |
| 2024-09-30 | -32.17K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 45.77K shares derived: sum of 2 quarters · filed 2024-11-12 | 98.06K shares 10-Q · filed 2024-11-12 | 319.91K shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 77.95K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 130.23K shares 10-Q · filed 2024-08-14 | 352.09K shares derived: sum of 3 quarters · filed 2024-08-14 | 461.85K shares derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | 52.29K shares 10-Q · filed 2024-05-14 | 274.14K shares derived: sum of 2 quarters · filed 2024-05-14 | 383.90K shares derived: sum of 3 quarters · filed 2024-05-14 | |
| 2023-12-31 | 221.85K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 331.62K shares derived: sum of 2 quarters · filed 2024-03-21 | 724.02K shares 10-K · filed 2024-03-21 | |
| 2023-09-30 | 109.76K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 502.16K shares 10-Q · filed 2023-11-07 | ||
| 2023-06-30 | 392.40K shares 10-Q · filed 2023-08-11 | |||
| 2022-12-31 | 118.76K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | 231.05K shares derived: sum of 2 quarters · filed 2023-03-22 | 771.50K shares derived: sum of 3 quarters · filed 2023-03-22 | 834.10K shares 10-K · filed 2023-03-22 |
| 2022-09-30 | 112.29K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | 652.73K shares derived: sum of 2 quarters · filed 2022-11-01 | 715.33K shares 10-Q · filed 2022-11-01 | 944.51K shares derived: sum of 4 quarters · filed 2022-11-01 |
| 2022-06-30 | 540.45K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 603.04K shares 10-Q · filed 2022-08-15 | 832.22K shares derived: sum of 3 quarters · filed 2022-08-15 | |
| 2022-03-31 | 62.60K shares 10-Q · filed 2022-05-13 | 291.78K shares derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2021-12-31 | 229.18K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 574.84K shares 10-K · filed 2022-03-29 | ||
| 2021-09-30 | 345.66K shares 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |